Literature DB >> 23416172

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease.

Julien Dumurgier1, Audrey Gabelle, Olivier Vercruysse, Stéphanie Bombois, Jean-Louis Laplanche, Katell Peoc'h, Susanna Schraen, Bernard Sablonnière, Florence Pasquier, Jacques Touchon, Sylvain Lehmann, Jacques Hugon, Claire Paquet.   

Abstract

Increasing age is the most important risk factor for developing Alzheimer's disease (AD). The aim of this study was to investigate the relationships between age and cerebrospinal fluid (CSF) levels of β-amyloid (Aβ 1-42), total Tau and phosphorylated Tau (pTau-181), in AD and non-AD patients explored for cognitive disorders. 966 patients (AD, n=528; non-AD, n=438) were included between January 2008 and December 2010 (mean age, 69.5years; mean MMSE, 20.2) from three French memory centers. Multivariable linear regression models were used to study the relationship between CSF biomarker levels and age in AD and non-AD patients. The capacity of each CSF biomarker in discriminating patients was evaluated using the area under the receiver-operating characteristic (ROC) curves by quartile of distribution of age. In AD patients, older age was associated with higher CSF Aβ 1-42 and lower Tau levels. Conversely, in non-AD patients, age was associated with lower CSF Aβ 1-42, higher Tau, and higher pTau-181 levels. In sex-stratified analysis, these relationships were significant only in women. Using ROC curve analysis, CSF AD biomarkers were more discriminant in younger patients than in older ones. In this clinically-based study, younger patients with AD had exacerbated CSF anomalies compared to older patients with AD. CSF biomarkers were more discriminant in younger patients than in older ones for the diagnosis of AD, especially in women. These results support the idea of an overlap in AD neuropathological lesions in oldest subjects with or without AD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416172     DOI: 10.1016/j.nbd.2013.01.023

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  9 in total

1.  The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.

Authors:  Alice Jaillard; Matthieu Vanhoutte; Aurélien Maureille; Susanna Schraen; Emilie Skrobala; Xavier Delbeuck; Adeline Rollin-Sillaire; Florence Pasquier; Stéphanie Bombois; Franck Semah
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-28       Impact factor: 9.236

2.  Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease.

Authors:  Josephine Barnes; Jonathan W Bartlett; David A Wolk; Wiesje M van der Flier; Chris Frost
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Differences in Multimodal Electroencephalogram and Clinical Correlations Between Early-Onset Alzheimer's Disease and Frontotemporal Dementia.

Authors:  Nan Lin; Jing Gao; Chenhui Mao; Heyang Sun; Qiang Lu; Liying Cui
Journal:  Front Neurosci       Date:  2021-08-05       Impact factor: 4.677

4.  Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study.

Authors:  François Mouton-Liger; David Wallon; Anne-Cécile Troussière; Rachida Yatimi; Julien Dumurgier; Eloi Magnin; Vincent de la Sayette; Emannuelle Duron; Nathalie Philippi; Emilie Beaufils; Audrey Gabelle; Bernard Croisile; Philippe Robert; Florence Pasquier; Didier Hannequin; Jacques Hugon; Claire Paquet
Journal:  J Neurol       Date:  2013-10-27       Impact factor: 4.849

5.  Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

Authors:  Julien Dumurgier; Susanna Schraen; Audrey Gabelle; Olivier Vercruysse; Stéphanie Bombois; Jean-Louis Laplanche; Katell Peoc'h; Bernard Sablonnière; Ksenia V Kastanenka; Constance Delaby; Florence Pasquier; Jacques Touchon; Jacques Hugon; Claire Paquet; Sylvain Lehmann
Journal:  Alzheimers Res Ther       Date:  2015-06-01       Impact factor: 6.982

Review 6.  Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.

Authors:  Jin-A Mo; Ju-Hee Lim; Ah-Ram Sul; Min Lee; Young Chul Youn; Hee-Jin Kim
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

7.  Brain intraventricular injection of amyloid-β in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithium.

Authors:  Laura Roesler Nery; Natalia Silva Eltz; Cristiana Hackman; Raphaela Fonseca; Stefani Altenhofen; Heydi Noriega Guerra; Vanessa Morais Freitas; Carla Denise Bonan; Monica Ryff Moreira Roca Vianna
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

8.  Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study.

Authors:  Claire Paquet; Eloi Magnin; David Wallon; Anne-Cécile Troussière; Julien Dumurgier; Alain Jager; Frank Bellivier; Elodie Bouaziz-Amar; Frédéric Blanc; Emilie Beaufils; Carole Miguet-Alfonsi; Muriel Quillard; Susanna Schraen; Florence Pasquier; Didier Hannequin; Philippe Robert; Jacques Hugon; François Mouton-Liger
Journal:  Alzheimers Res Ther       Date:  2016-06-13       Impact factor: 6.982

9.  Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

Authors:  Sylvain Lehmann; Constance Delaby; Guilaine Boursier; Cindy Catteau; Nelly Ginestet; Laurent Tiers; Aleksandra Maceski; Sophie Navucet; Claire Paquet; Julien Dumurgier; Eugeen Vanmechelen; Hugo Vanderstichele; Audrey Gabelle
Journal:  Front Aging Neurosci       Date:  2018-05-28       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.